FDA Finalizes Heart Safety Labels for Drugs – QTc Gets the Nod
Published Date: 12/3/2025
Notice
Summary
The FDA just released new guidance to help drug makers include important heart safety info (QTc interval) in their prescription drug and biological product labels. This update affects companies making non-heart rhythm drugs and helps them show this info clearly and correctly. The guidance is final as of December 3, 2025, so companies should start updating labels soon to stay on track and avoid delays or extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
QTc Safety Info Added to Patient Labels
If you take a prescription drug or biological product that is not a heart-rhythm (antiarrhythmic) medicine, FDA's final guidance published December 3, 2025 recommends including clinically relevant heart rate–corrected QT (QTc) interval prolongation information in product labeling. The guidance specifically adds recommendations for including QTc information in FDA‑approved patient labeling and for updating QTc information in currently‑approved labeling.
Early QTc Assessment in Drug Development
The guidance recommends that applicants for most non‑antiarrhythmic drugs with systemic bioavailability assess effects on cardiac repolarization early in clinical development, including a clinical electrocardiographic (ECG) evaluation. The guidance states the QTc assessment in early development may inform the frequency and continuation of ECG monitoring in late‑phase clinical trials.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-21797, Combined Notice of Filings
Several natural gas companies have filed requests to update their pipeline rates and agreements, with most changes starting January 1, 2026. These updates could affect how much customers pay for gas transportation and how companies manage fuel use. If you want to share your thoughts, you have until early December to comment before the new rates kick in.
Next: 2025-21799, Florida Gas Transmission Company, LLC; Notice of Request Under Blanket Authorization and Establishing Intervention and Protest Deadline
Florida Gas Transmission Company wants to upgrade its natural gas pipeline in parts of Mississippi, Alabama, and Florida to move more gas—up to 170,000 MMBtu per day! This $67.5 million project will help meet growing energy needs in the South Central Alabama area. If you’re interested, you’ve got until the protest deadline to speak up or get involved.